Neuland Laboratories Limited (NSE:NEULANDLAB)
India · Delayed Price · Currency is INR 19,620
+196 (1.01%)
Nov 4, 2026, 3:29 PM IST
Neuland Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 23,072 | 20,230 | 14,768 | 15,586 | 11,912 | 9,511 |
Other Revenue | 63.31 | - | - | - | 2.88 | 5.99 |
| 23,135 | 20,230 | 14,768 | 15,586 | 11,915 | 9,517 | |
Revenue Growth | 50.87% | 36.98% | -5.24% | 30.81% | 25.20% | 1.57% |
Cost of Revenue | 10,425 | 9,471 | 7,505 | 7,338 | 6,138 | 5,535 |
Gross Profit | 12,711 | 10,759 | 7,263 | 8,248 | 5,777 | 3,982 |
Selling, General & Admin | 3,971 | 3,427 | 2,734 | 2,580 | 2,026 | 1,832 |
Other Operating Expenses | 1,575 | 1,534 | 1,224 | 1,038 | 917.43 | 698.58 |
Operating Expenses | 6,589 | 5,878 | 4,613 | 4,214 | 3,471 | 3,021 |
Operating Income | 6,122 | 4,880 | 2,650 | 4,033 | 2,306 | 960.9 |
Interest Expense | -230.24 | -186.97 | -57.89 | -110.74 | -104.02 | -95.34 |
Interest & Investment Income | 100.55 | 100.55 | 105.84 | 82.27 | 15.56 | 9.95 |
Currency Exchange Gain (Loss) | 105.65 | 105.65 | 5.96 | -0.55 | -103.33 | -1.02 |
Other Non Operating Income (Expenses) | -52.51 | -52.51 | -25.08 | -29.23 | -21.45 | -34.79 |
EBT Excluding Unusual Items | 6,045 | 4,847 | 2,679 | 3,975 | 2,092 | 839.71 |
Gain (Loss) on Sale of Investments | 75.55 | 75.55 | 76.83 | - | - | - |
Gain (Loss) on Sale of Assets | -52.74 | -52.74 | -73.11 | -4.02 | -8.71 | -18.08 |
Other Unusual Items | 19.92 | 19.92 | 779.58 | 40.36 | 37.85 | - |
Pretax Income | 6,088 | 4,890 | 3,463 | 4,014 | 2,157 | 821.63 |
Income Tax Expense | 1,563 | 1,250 | 862.21 | 1,014 | 522.29 | 183.41 |
Earnings From Continuing Operations | 4,525 | 3,640 | 2,601 | 3,001 | 1,635 | 638.22 |
Net Income | 4,525 | 3,640 | 2,601 | 3,001 | 1,635 | 638.22 |
Net Income to Common | 4,525 | 3,640 | 2,601 | 3,001 | 1,635 | 638.22 |
Net Income Growth | 88.44% | 39.94% | -13.32% | 83.52% | 156.21% | -20.85% |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Change | -0.00% | - | - | - | - | - |
EPS (Basic) | 352.74 | 283.71 | 202.74 | 233.89 | 127.45 | 49.74 |
EPS (Diluted) | 352.74 | 283.71 | 202.74 | 233.89 | 127.45 | 49.74 |
EPS Growth | 88.45% | 39.94% | -13.32% | 83.52% | 156.23% | -20.85% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 2,580 | -504.52 | 1,109 | 1,175 | 1,711 | -372.97 |
Free Cash Flow Per Share | 201.10 | -39.32 | 86.47 | 91.59 | 133.35 | -29.07 |
Dividend Per Share | - | 34.000 | 12.000 | 14.000 | 10.000 | 5.000 |
Dividend Growth | - | 183.33% | -14.29% | 40.00% | 100.00% | 0% |
Gross Margin | 54.94% | 53.18% | 49.18% | 52.92% | 48.49% | 41.84% |
Operating Margin | 26.46% | 24.12% | 17.95% | 25.88% | 19.35% | 10.10% |
Profit Margin | 19.56% | 17.99% | 17.61% | 19.25% | 13.72% | 6.71% |
Free Cash Flow Margin | 11.15% | -2.49% | 7.51% | 7.54% | 14.36% | -3.92% |
EBITDA | 7,043 | 5,675 | 3,243 | 4,588 | 2,792 | 1,404 |
EBITDA Margin | 30.44% | 28.05% | 21.96% | 29.44% | 23.43% | 14.75% |
D&A For EBITDA | 920.76 | 794.73 | 593.07 | 554.31 | 486.2 | 443.13 |
EBIT | 6,122 | 4,880 | 2,650 | 4,033 | 2,306 | 960.9 |
EBIT Margin | 26.46% | 24.12% | 17.95% | 25.88% | 19.35% | 10.10% |
Effective Tax Rate | 25.67% | 25.56% | 24.90% | 25.25% | 24.21% | 22.32% |
Revenue as Reported | 23,437 | 20,532 | 14,973 | 15,711 | 12,009 | 9,532 |